Academic pharmacist Nataly Martini highlights the importance of understanding non-Hodgkin lymphoma and pharmacists’ roles in managing this condition
Friday 1 November 2024, 01:00 AM
14 minutes to Read
CLASStime: Beyond medicines for gout
+Class
In print
summer hiatus
CLASStime: Beyond medicines for gout
Thursday 6 January 2022, 09:00 AM
We are on our summer break and the editorial office is closed until 17 January. In the meantime, please enjoy our Summer Hiatus series, an eclectic mix from our news and clinical archives and articles from The Conversation throughout the year
In this CLASS article, Linda Bryant discusses gout, a chronic long-term condition that is often associated with other diseases, and drug-related morbidity and mortality. As such, gout needs to be addressed holistically as part of the psychosocial medical model
HAH_Support
References
1. Health Quality & Safety Commission New Zealand. Atlas of Healthcare Variation: Gout. 2021. https://tinyurl.com/HQSCgout
2. Dalbeth N, House ME, Horne A, et al. The experience and impact of gout in Māori and Pacific people: a prospective observational study. Clin Rheum 2013;32(2):247–51.
3. Ministry of Health. Pharmaceutical Collection. People starting preventative gout medication for the first time between 1 June 2016 and 30 June 2020 aged 15+ years. https://tinyurl.com/hlthstats
4. Dalbeth N, Dowell T, Gerard C, et al. Gout in Aotearoa New Zealand: the equity crisis continues in plain sight. N Z Med J 2018;131(1485):8–12.
5. Gill I, Dalbeth N, Ofanoa M, et al. Interventions to improve uptake of urate-lowering therapy in patients with gout: A systematic review. BJGP Open 2020;4(3): bjgpopen20X101051.
6. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008;336(7639):309–12.
7. Hueskes B, Roovers E, Mantel-Teeuwisse A, et al. Use of diuretics and the risk of gouty arthritis: a systematic review. Semin Arthritis Rheum 2012;41(6):879–89.
8. Zhang Y, Neogi T, Chen C, et al. Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis 2014;73(2):385–90.
9. Stamp LK, Barclay ML, O'Donnell JL, et al. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice. Rheumatology (Oxford) 2012;51(9):1670–76.
10. Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007;57(1):109–15.
11. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford) 2013;52(1):34–44.
12. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116(8):894–900.
13. Liu X, Sun D, Ma X, et al. Benefit-risk of corticosteroids in acute gout patients: An updated meta-analysis and economic evaluation. Steroids 2017;128:89–94.
14. Roddy E, Clarkson K, Blagojevic-Bucknall M, et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis 2020;79(2):276–84.
15. Jayaprakash V, Ansell G, Galler D. Colchicine overdose: the devil is in the detail. N Z Med J 2007;120:U2402.
16. Tomlin A, Woods DJ, Lambie A, et al. Ethnic inequality in non-steroidal anti-inflammatory drug-associated harm in New Zealand: A national population-based cohort study. Pharmacoepidemiol Drug Saf 2020;29(8):881–89.
17. BPACnz. Managing gout in primary care. August 2021. https://bpac.org.nz/2021/docs/gout2021.pdf
18. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11(2):R46.
19. Eminaga F, Le-Carratt J, Jones A, et al. Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. Rheumatol Int 2016;36(12):1747–52.
20. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 2020; 72(6):744–60.
21. Borstad G, Bryant L, Abel M, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for gouty arthritis. J Rheumatol 2004.31(12):2429–32.
22. Stamp L, Taylor W, Jones P, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome. Arthritis Rheum 2012;64(8):2529–36.
23. A. Menarini New Zealand Pty Ltd. New Zealand Datasheet: Adenuric® 80 mg, 120 mg film coated tablets. August 2019. medsafe.govt.nz
24. Soffer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26(1):112–17.
25. Ohshiro K, Sakima A, Nakada S, et al. Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients. Clin Exp Hypertens 2011;33(8):565–70.
Class archive
Class
Hosted Content 2
Talking about butt stuff in the pharmacy can be awkward. Care Pharmaceuticals and Rectogesic® can help you get to the bottom of the issue
Monday 1 July 2024, 08:00 AM
1 minute to Read
Latest issue
